Canaccord Genuity Group Predicts Veru Q3 Earnings

Veru Inc. (NASDAQ:VERU) – Research analysts at Canaccord Genuity Group issued their Q3 2026 earnings per share estimates for shares of Veru in a note issued to investors on Thursday, August 6th. Canaccord Genuity Group analyst E. Nash expects that the company will earn ($0.30) per share for the quarter. Canaccord Genuity Group currently has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Veru’s current full-year earnings is ($1.07) per share.

Several other brokerages have also recently weighed in on VERU. Weiss Ratings raised shares of Veru from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 5th. Oppenheimer cut their price objective on shares of Veru from $25.00 to $24.00 and set an “outperform” rating on the stock in a report on Friday, May 15th. Finally, Wall Street Zen raised shares of Veru to a “hold” rating in a research note on Sunday, July 12th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $23.00.

Veru Price Performance

Shares of Veru stock opened at $2.77 on Monday. The stock has a market cap of $44.46 million, a price-to-earnings ratio of -3.11 and a beta of -1.15. The firm’s 50-day moving average is $2.72 and its two-hundred day moving average is $2.50. Veru has a 1 year low of $2.05 and a 1 year high of $7.33.

Veru (NASDAQ:VERU) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.02.

Institutional Trading of Veru

Several hedge funds have recently modified their holdings of VERU. ADAR1 Capital Management LLC bought a new position in shares of Veru during the 4th quarter worth approximately $75,000. Blair William & Co. IL boosted its stake in Veru by 26.3% in the fourth quarter. Blair William & Co. IL now owns 48,000 shares of the company’s stock valued at $103,000 after acquiring an additional 10,000 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Veru in the third quarter valued at approximately $110,000. Osaic Holdings Inc. grew its holdings in Veru by 11.9% in the second quarter. Osaic Holdings Inc. now owns 262,820 shares of the company’s stock worth $152,000 after purchasing an additional 27,954 shares during the last quarter. Finally, Sender Co & Partners Inc. grew its holdings in Veru by 82.8% in the second quarter. Sender Co & Partners Inc. now owns 238,231 shares of the company’s stock worth $139,000 after purchasing an additional 107,911 shares during the last quarter. 47.16% of the stock is owned by hedge funds and other institutional investors.

Veru Company Profile

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.